Collaborative Decision-Making for Extended Endocrine Therapy in Early-Stage, HR+ Breast Cancer

Collaborative Decision-Making for Extended Endocrine Therapy in Early-Stage, HR+ Breast Cancer

*Linda Moors, PA-C is a consultant of Biotheranostics, Inc. Statements reflect the speakers’ own personal views and interpretations.

For the Breast Cancer Index test Intended Use and Limitations, visit breastcancerindex.com

© 2025 Hologic, Inc. Hologic, Biotheranostics, Breast Cancer Index, BCI, and associated logos are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries. All other trademarks are the property of their respective owners.